AGENDA

INTRODUCTION AND OPERATIONAL DELIVERY Page 3

COVID-19 OVERVIEW Page 8

FINANCIAL REVIEW Page 14

STRATEGIC DELIVERY Page 17

QUESTIONS Page 25

ANNEXURE Page 26
INTRODUCTION AND OPERATIONAL DELIVERY
### FACILITIES TREATING PATIENTS ACROSS THE CONTINUUM OF CARE

**At 30 September 2020**

<table>
<thead>
<tr>
<th>DIVISIONS</th>
<th>INVESTMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIRSLANDEN</td>
<td>MEDICLINIC SOUTHERN AFRICA</td>
</tr>
<tr>
<td><strong>BEDS</strong></td>
<td>1,921</td>
</tr>
<tr>
<td><strong>HOSPITALS</strong></td>
<td>17</td>
</tr>
<tr>
<td><strong>SUB-ACUTE &amp; SPECIALISED HOSPITALS</strong></td>
<td>-</td>
</tr>
<tr>
<td><strong>DAY CASE CLINICS</strong></td>
<td>4</td>
</tr>
<tr>
<td><strong>OUTPATIENT CLINICS</strong></td>
<td>-</td>
</tr>
<tr>
<td><strong>MARKET POSITION</strong></td>
<td>#1</td>
</tr>
</tbody>
</table>

\(^1\)Minority investment in Intercare’s 22 multi-disciplinary primary care medical and dental centres

---

**MEDICLINIC PARKVIEW HOSPITAL DUBAI**
DIVERSIFIED HEALTHCARE SERVICES GROUP WITH LEADING MARKET POSITIONS

- **Over 35 years’ experience** of delivering healthcare services; now operating on **three continents**
- **Expertise** across a **broad range of clinical services**
- Around **50%** of Group revenue represented by non-elective specialist acute inpatient services and emergency care
- Treated over **763,000 inpatients** in FY20
- Leveraging acute care infrastructure and knowledge to **expand geographically** and **across the continuum of care**
- Around **95%** of Group revenue generated from **insured patients**

8 HOSPITALS in top 25 for Switzerland according to Newsweek’s list of World’s Best Hospitals

6 HOSPITALS on Discovery Health top 20 Hospital List based on patient surveys in 2019

5 OUT OF 6 YEARS awarded Superbrand status by UAE’s Superbrands Council

---

**FY20 GROUP REVENUE CONTRIBUTION**

- **Accute inpatient care**: 69%
- **Outpatient care**: 23%
- **Day case care**: 8%

**Note:**

- General Medicine includes services offered by general practitioners and allied health professionals

---

MEDICLINIC INTERNATIONAL OVERVIEW PRESENTATION | JANUARY 2021
<table>
<thead>
<tr>
<th>Description</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fulfilling an <strong>essential role</strong> in combatting the pandemic</td>
<td>Unwavering <strong>commitment and resilience</strong> from our people</td>
</tr>
<tr>
<td>Significant financial impact in April 2020; <strong>rebound</strong> in</td>
<td>Retained <strong>strong financial position and liquidity</strong></td>
</tr>
<tr>
<td>trading from May 2020</td>
<td></td>
</tr>
</tbody>
</table>
CONTINUED OPERATIONAL DELIVERY

Offering convenient, cost-efficient integrated care
- Acquired Opera day case clinic and opened Opera St Gallen
- Opened co-located day case clinic at Mediclinic Cape Gate; additional facility opened at Bloemfontein
- Procurement efficiencies supported by hystrix and Sana partnerships
- Advancing Medbase relationship; creating national primary care network
- Opening of Comprehensive Cancer Centre at Mediclinic Airport Road Hospital imminent
- EHR rollout on track; recent go-lives at Mediclinic Airport Road, Al Jowhara and Al Ain

Leveraging skills and synergies through partnerships and collaboration
- Partnership established in fields of urology and cardiology with cantonal hospital Schaffhausen
- Establishing private partnership in the field of cardiology with Spital Lachen
- Entered management contract to operate a hospital in Abu Dhabi

Delivering clinical excellence
- Breast cancer centre at Salem and Linde hospitals certified by the Swiss Cancer League
- Mediclinic City Hospital implemented robotic surgery using da Vinci Xi HD 4-arm robotic system
- Mediclinic Airport Road Hospital Metabolic and Bariatric Surgery accredited as Centre of Excellence by Surgical Review Corporation
COVID-19 OVERVIEW
EFFECTIVELY NAVIGATING THE PANDEMIC
FULFILLING A VITAL ROLE

Safety of employees and patients

Maintained staffing levels

Continuity of operations

Safely reintroduced non-urgent elective procedures and outpatient activity

Support of and collaboration with health authorities

Multi-disciplinary taskforces at Group and divisional level
Gatherings knowledge  
Textbook preparation  

Implement  
Face reality  

Vaccination  
New normal
FIRST WAVE VS SECOND WAVE
HIRSLANDEN AND MEDICLINIC SOUTHERN AFRICA

TOTAL COVID-19 ADMISSIONS PER WEEK
HIRSLANDEN

FIRST WAVE
Peak: 54 admissions in a week

SECOND WAVE
Peak: 71 admissions in a week

TOTAL COVID-19 ADMISSIONS PER WEEK
MEDICLINIC SOUTHERN AFRICA

Peak: 1 300 admissions in a week

Peak: 3 200 admissions in a week
COVID-19 OVERVIEW

- Variants
- Vaccines
- Re-infections
- Long COVID-19
- Treatment
BENEFITING FROM OUR INTERNATIONAL PERSPECTIVE

Centrally coordinated clinical response

Central analytics team incorporated epidemiological models into forecasts

Shared learnings optimised treatment modalities and care pathways

Improved relations with specialists and primary care physicians through technology adoption

Maintained sufficient supplies of PPE and consumables

Continued strategy execution and expansion across the continuum of care
• Lockdowns and restrictions suspending non-urgent elective procedures significantly impacted revenue and profitability in April 2020
• Strong rebound at Hirslanden and Mediclinic Middle East as restrictions were lifted
• Gradual recovery at Mediclinic Southern Africa following initial peak of the pandemic in August 2020

• Ongoing impact of COVID-19 on in- and outpatient activity partially offset by COVID-19-related and additional revenue streams
• Progressive cost management
• Remain cautious on impact of the pandemic and its economic aftermath on near-term performance
FINANCIAL REVIEW – Q3 FY21 TRADING UPDATE

Q3 FY21 Revenue and profitability

- Group revenue up 2.5%; EBITDA margin 17.0% (Q3 FY20: 19.0%)
- Hirslanden revenue down 1.5%; EBITDA margin 16.5% (Q3 FY20: 18.9%)
- Mediclinic Southern Africa revenue up 3.5%; EBITDA margin 21.0% (Q3 FY20: 19.4%)
- Mediclinic Middle East revenue up 8.0%; EBITDA margin 13.5% (Q3 FY20: 18.3%)

Cash and liquidity

- Cash and available facilities end December 2020 - maintained at around £660m
- Improving YTD Group cash conversion at 59% (1H21: 42%) of adjusted EBITDA; target remains 90-100%

Leverage

- Group net debt reduced during Q3 following CHF50m optional debt repayment at Hirslanden
- Covenant test waivers in place until June (MCME) and September 2021 (Hirslanden and MCSA)
- Maturities proactively managed

Returns

- ROIC at 3.2%, distorted by operating performance
- Focus on improved asset turnover
STRATEGIC DELIVERY
DELIVERY AND EXECUTION OF GROUP STRATEGY
ACCELERATED DURING THE PANDEMIC

PURPOSE
Our purpose is to enhance the quality of life.

VISION
Our vision is to be the partner of choice that people trust for all their healthcare needs.

OUR STRATEGIC GOALS ARE TO:

Goal 1: To become an integrated healthcare provider across the continuum of care;

Goal 2: To improve our value proposition significantly;

Goal 3: To transform our healthcare services and client engagement through digitalisation;

Goal 4: To evolve as an analytics-driven organisation;

Goal 5: To strengthen our position as the employer of choice;

Goal 6: To grow in existing markets and expand into new markets; and

Goal 7: To achieve superior long-term financial returns

Transformation Driver 1: Innovation
Transformation Driver 2: Sustainable development

ALIGNED ACROSS ALL DIVISIONS
EXPANDING ACROSS THE CONTINUUM OF CARE
IN SUPPORT OF OUR VISION

DAY CASE CLINICS
SPECIALISED HOSPITALS
ACUTE CARE HOSPITALS
SUB-ACUTE HOSPITALS
OUTPATIENT CLINICS
DIAGNOSTICS
GENETIC SERVICES
IVF
TELEMEDICINE

PREVENT
ENHANCE
RECOVER
CARE

TO ENHANCE THE QUALITY OF LIFE

VISION
To be the partner of choice that people trust for all their healthcare needs

PARTNERSHIPS

GROWTH

VALUE

EQUATION

INNOVATION

DIGITALISATION

ANALYTICS

EXPANSION

MEDICLINIC INTERNATIONAL OVERVIEW PRESENTATION | JANUARY 2021
Deploying a healthcare digital backbone

Enhancing our B2C capability

Enabling expansion of our virtual care solutions
DIGITALISATION AND INNOVATION

ACHIEVEMENTS IN 2020

**Automation**
- Opportunities in robotic process automation, integrated machine learning, AI
- Adopted UIPath as Group standard for automation
- Hirslanden automated multiple back-office processes and identified 100+ automation opportunities
- Group pilot reduced three-week process to 21 minutes

**Platform**
- Platform to aggregate and manage digital continuum of care
- Hirslanden pilot by March 2021
- South African pilot due early 2021

**Telemedicine**
- Developed as alternative revenue stream at MCME and as alternative access path for patients
- ICU collaborative sessions to support COVID-19 care connected all three divisions

**Remote care**
- Virtual ICU pilot in South Africa connecting ICU medical devices to doctors remotely for review and augmented care
- Chronic and COVID-19 monitoring application launched at MCME to facilitate remote care

**Virtual care**

**Innovation**
- Appointed Group Chief Innovation Officer
- Finalised Group Innovation Strategy
- Established Mediclinic Precise, a comprehensive genetics service, at MCME
- Hirslanden Precise launch planned for May 2021
COMMITTED TO SUSTAINABLE DEVELOPMENT

GROUP ACHIEVEMENTS

Obtained Prime status from ISS-ESG on ESG performance

Ranked 32nd globally on REFINITIV Diversity and Inclusion Index, the top ranking ‘Healthcare Providers and Services’ company

Maintained top MSCI ESG AAA rating for third consecutive year

Became signatory of epihc, an initiative by the International Finance Corporation and World Bank

Constituent of the FTSE4Good UK Index
WELL POSITIONED FOR LONG-TERM INDUSTRY TRENDS
RETURNING TO GROWTH IN FY22

Focused on future growth through operational delivery and strategy execution

Accelerating virtual care initiatives to address changing client needs

Pursue opportunities across the continuum of care
QUESTIONS
GROUP OUTLOOK

- Demand for the Mediclinic’s broad range of healthcare services remains strong and the Group is confident that this, together with its strategy execution and operational delivery, will drive long-term performance. In the short-term, the Group remains suitably cautious on its 2H21 performance in the midst of uncertainty as to the severity, duration and full impact of the continuing pandemic, as well as its economic aftermath.

- The divisional outlooks below do not reflect the impact on the business of severe restrictions such as those imposed by authorities in April 2020, which suspended the provision of non-urgent elective procedures.

- Europe is now experiencing a second wave of the pandemic and while the severe restrictions on elective procedures implemented in March and April 2020 have not yet been implemented, the second wave is expected to impact on hospital and outpatient revenues. When combined with a similar cost profile to 1H21, the division expects 2H21 revenue and EBITDA to be broadly in line with 2H20.

- The initial peak of the pandemic only recently passed across the region with Mediclinic currently still caring for sizable numbers of COVID-19 patients. As such, Mediclinic Southern Africa has not yet experienced the same rebound witnessed in the other two divisions. Considering this in combination with the potential macroeconomic impact and consequent effect on medical scheme membership, the division currently expects the recent revenue trend, as reported for the month of September 2020, to broadly continue through 2H21. With improved cost efficiencies, the EBITDA margin is expected to improve from that experienced in 1H21.

- The encouraging underlying 1H21 improvement in volumes was supported by counter-seasonal holiday trends resulting from imposed travel restrictions and COVID-19-related and alternative initiatives. With the region now experiencing a second wave of the pandemic, non-COVID-19-related patient activity could be impacted while less than 50% of COVID-19-related initiatives in 1H21 are expected in 2H21. The counter-seasonal benefit in 1H21 is expected to unwind during the December and January holiday period, impacting patient activity. Coupled with macroeconomic uncertainty and the consequent impact on the expatriate population, the division expects to deliver modest revenue growth in 2H21 compared with the prior year period. The EBITDA margin is expected to be temporarily impacted in 2H21 compared with 2H20 due to the described revenue impact and start-up costs associated with opening the CCC and expansion at Mediclinic Airport Road Hospital.

- The Group recognises significant uncertainty and volatility is expected to remain for at least the following 18 months due to the pandemic. However, the current expectation is for Group revenue and EBITDA in FY22 to be broadly in line with FY20. Growth will be most notable at Mediclinic Middle East given prior year investments continuing to ramp up, while the recovery at Mediclinic Southern Africa is likely to be the most gradual over time, given the macroeconomic outlook.
**DISCIPLINED CAPITAL ALLOCATION SUPPORTS LONG-TERM GROWTH AND RETURNS**

<table>
<thead>
<tr>
<th>FY20 Actual capex (£'m)</th>
<th>Hirslanden</th>
<th>Southern Africa</th>
<th>Middle East</th>
<th>Corporate</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>To maintain operations</td>
<td>35</td>
<td>39</td>
<td>10</td>
<td>-</td>
<td>84</td>
</tr>
<tr>
<td>To expand operations</td>
<td>40</td>
<td>31</td>
<td>36</td>
<td>1</td>
<td>108</td>
</tr>
<tr>
<td>Total capital expenditure</td>
<td>75</td>
<td>70</td>
<td>46</td>
<td>1</td>
<td>192</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>FY21 Forecast capex (£'m)¹</th>
<th>Hirslanden</th>
<th>Southern Africa</th>
<th>Middle East</th>
<th>Corporate</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>To maintain operations</td>
<td>40</td>
<td>18</td>
<td>13</td>
<td>-</td>
<td>71</td>
</tr>
<tr>
<td>To expand operations</td>
<td>32</td>
<td>25</td>
<td>45</td>
<td>-</td>
<td>102</td>
</tr>
<tr>
<td>Total capital expenditure</td>
<td>72</td>
<td>43</td>
<td>58</td>
<td>-</td>
<td>173</td>
</tr>
</tbody>
</table>

¹ Constant currency basis: GBP/CHF: 1.25, GBP/ZAR: 18.76, GBP/AED: 4.67

- In line with expected improvements in operating cash flows, the Group currently plans to proportionately increase the annual capex investment at Hirslanden while continuing to generate appropriate free cash flow to equity holders (including the continued annual debt amortisation). Over the medium term, maintenance capex is expected to be between 4.5-5.5% of revenue while expansion capex will incorporate the seven-year investment at Klinik St Anna and Klinik Aarau.

- The division continues with its multi-year maintenance and upgrade cycle, with medium-term expectations from FY22 onwards for the ratio of maintenance capex to revenue averaging around 3% which combined with reductions over time of expansion projects will result in annual capex of around ZAR1bn.

- Major expansion projects at Mediclinic Middle East are nearing completion and following FY21, capex will decline over the following two years, stabilising at around 50% of the FY21 budget from FY23.
## Mediclinic Southern Africa

<table>
<thead>
<tr>
<th>Carrying value</th>
<th>Carrying value</th>
<th>Terms</th>
<th>Date repayable</th>
</tr>
</thead>
<tbody>
<tr>
<td>ZARm</td>
<td>£’m</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Senior terms</td>
<td>6 174</td>
<td>287</td>
<td>3M Jibar +1.49% (ZAR2 585m) and +1.59% (ZAR3 589m)</td>
</tr>
<tr>
<td>Preference shares</td>
<td>1 806</td>
<td>84</td>
<td>3M Jibar x 72% +1.65%</td>
</tr>
<tr>
<td>Subsidiaries</td>
<td>80</td>
<td>4</td>
<td>Rates linked to prime interest rate</td>
</tr>
<tr>
<td><strong>Total debt</strong></td>
<td><strong>8 060</strong></td>
<td><strong>375</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Cash and cash equivalents</strong></td>
<td><strong>(1 061)</strong></td>
<td><strong>(49)</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Interest expense</strong></td>
<td><strong>276</strong></td>
<td><strong>13</strong></td>
<td></td>
</tr>
</tbody>
</table>

## Hirslanden

<table>
<thead>
<tr>
<th>CHFm</th>
<th>£’m</th>
<th>Terms</th>
<th>Date repayable</th>
</tr>
</thead>
<tbody>
<tr>
<td>Secured long-term bank loans</td>
<td>1 385</td>
<td>1 164</td>
<td>Swiss 3M Libor +1.25%</td>
</tr>
<tr>
<td>Other secured bank loans</td>
<td>28</td>
<td>24</td>
<td>CHF10m 0.9%, CHF18m 1.12%</td>
</tr>
<tr>
<td>Swiss bonds</td>
<td>235</td>
<td>198</td>
<td>CHF145m at 1.625%, CHF90m at 2.0%</td>
</tr>
<tr>
<td><strong>Total debt</strong></td>
<td><strong>1 648</strong></td>
<td><strong>1 385</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Cash and cash equivalents</strong></td>
<td><strong>(149)</strong></td>
<td><strong>(126)</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Interest expense</strong></td>
<td><strong>15</strong></td>
<td><strong>12</strong></td>
<td></td>
</tr>
</tbody>
</table>

## Mediclinic Middle East

<table>
<thead>
<tr>
<th>AEDm</th>
<th>£’m</th>
<th>Terms</th>
<th>Date repayable</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bank loans</td>
<td>904</td>
<td>190</td>
<td>3M Libor +1.85% with five-year amortising terms</td>
</tr>
<tr>
<td><strong>Total debt</strong></td>
<td><strong>904</strong></td>
<td><strong>190</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Cash and cash equivalents</strong></td>
<td><strong>(62)</strong></td>
<td><strong>(13)</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Interest expense</strong></td>
<td><strong>17</strong></td>
<td><strong>4</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Total Group interest expense (£’m)</strong></td>
<td><strong>29</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## Headroom to Divisional Covenants
### 30 September 2020

<table>
<thead>
<tr>
<th>Covenant</th>
<th>Status</th>
<th>Headroom variable</th>
<th>1H21 headroom</th>
<th>FY20 headroom</th>
<th>Compliant</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hirslanden</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leverage ratio</td>
<td>Waived(^2)</td>
<td>EBITDA</td>
<td>9%</td>
<td>17%</td>
<td>n/a</td>
</tr>
<tr>
<td>Economic capital ratio</td>
<td>Effective</td>
<td>Equity</td>
<td>30%</td>
<td>27%</td>
<td>Yes</td>
</tr>
<tr>
<td>Loan to value ratio</td>
<td>Effective</td>
<td>Property value</td>
<td>14%</td>
<td>17%</td>
<td>Yes</td>
</tr>
<tr>
<td><strong>MCSA</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leverage ratio</td>
<td>Waived(^2)</td>
<td>EBITDA</td>
<td>(4)%</td>
<td>37%</td>
<td>n/a</td>
</tr>
<tr>
<td>Net interest cover ratio</td>
<td>Waived(^2)</td>
<td>EBITDA</td>
<td>18%</td>
<td>47%</td>
<td>n/a</td>
</tr>
<tr>
<td><strong>MCME</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leverage ratio</td>
<td>Waived(^2)</td>
<td>EBITDA</td>
<td>37%</td>
<td>41%</td>
<td>n/a</td>
</tr>
<tr>
<td>Debt service coverage ratio</td>
<td>Waived(^2)</td>
<td>Cash flow</td>
<td>41%</td>
<td>80%</td>
<td>n/a</td>
</tr>
<tr>
<td>Minimum net worth</td>
<td>Effective</td>
<td>n/a</td>
<td>&gt;AED630m</td>
<td>&gt;AED750m</td>
<td>Yes</td>
</tr>
<tr>
<td>Minimum monthly receivables</td>
<td>Effective</td>
<td>n/a</td>
<td>&gt;AED190m(^3)</td>
<td>&gt;AED195m(^3)</td>
<td>Yes</td>
</tr>
</tbody>
</table>

1 Headroom is calculated with reference to the indicated headroom variable, keeping other inputs steady
2 Waived covenant compliance tests are to be performed at the end of June 2021 for Mediclinic Middle East and at the end of September 2021 for Mediclinic Southern Africa and Hirslanden
3 Average of last 3 months
Mediclinic's 29.9% investment in Spire gives the Group exposure to the UK private healthcare market

Spire is ideally positioned to be a leading player in the independent hospital sector given its scale, reach and quality of care

2020 interim results:
- Revenue down 18.2%
- Adjusted operating profit down 71.0%
- Net bank debt reduced 8.7%
- 90% of sites now rated ‘Good’, ‘Outstanding’ or equivalent

Outbreak of COVID-19 in the UK presents uncertainty for Spire
Suspended dividend payments in April 2020
Shown unwavering support to the NHS, agreeing to make nearly all 39 of its UK hospitals available to the NHS and its patients
Agreed new contract with NHS England in December 2020 to provide volume-based commitment aimed at reducing NHS waiting lists while continuing to treat private patients
Lenders have agreed to amend the June 2021 covenant test, with the next test in December 2021, and maturity of the Senior Loan Facility was extended by one year to July 2023
Anticipate FY20 adjusted operating profit significantly above previous guidance and year-end net bank debt position at the lower end of the previously guided range of £320m-£360m
Outlook (December 2020): Anticipate trading returning to 2019 levels in 2021
This presentation contains certain forward-looking statements relating to the business of the Company and its subsidiaries, including with respect to the progress, timing and completion of the Group’s development; the Group’s ability to treat, attract and retain patients and clients; its ability to engage consultants and general practitioners and to operate its business and increase referrals; the integration of prior acquisitions; the Group’s estimates for future performance and its estimates regarding anticipated operating results; future revenue; capital requirements; shareholder structure; and financing. In addition, even if the Group’s actual results or development are consistent with the forward-looking statements contained in this presentation, those results or developments may not be indicative of the Group’s results or developments in the future. In some cases, forward-looking statements can be identified by words such as “could”, “should”, “may”, “expects”, “aims”, “targets”, “anticipates”, “believes”, “intends”, “estimates”, or similar. These forward-looking statements are based largely on the Group’s current expectations as of the date of this presentation and are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievement expressed or implied by these forward-looking statements. In particular, the Group’s expectations could be affected by, among other things, uncertainties involved in the integration of acquisitions or new developments; changes in legislation or the regulatory regime governing healthcare in Switzerland, South Africa, Namibia and the United Arab Emirates; poor performance by healthcare practitioners who practise at its facilities; unexpected regulatory actions or suspensions; competition in general; the impact of global economic changes; and the Group’s ability to obtain or maintain accreditation or approval for its facilities or service lines. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements made in this presentation will in fact be realised and no representation or warranty is given as to the completeness or accuracy of the forward-looking statements contained in this presentation.

The Group is providing the information in this presentation as of this date, and disclaims any intention to, and make no undertaking to, publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.